Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Systemic Lupus Erythematosus: early-phase trial registry
43 of 100 indexed Systemic Lupus Erythematosus trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #136 of 28,707 conditions by registered trial count.
100 US clinical trials · 43 currently recruiting · #136 of 28,707 conditions by registered trial count
Systemic Lupus Erythematosus: 100 US clinical trials tracked, 43 recruiting.
Systemic Lupus Erythematosus is the subject of 100 registered US clinical trials on ClinicalTrials.gov, 43 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 54 in Phase 1-2 (earlier-stage). The most active sponsor is Bristol-Myers Squibb, running 6 of these trials.
Enrollment posture brief
Registry condition systemic-lupus-erythematosus
OPEN 43 | RECR 43% | LATE 21 | EARLY 54 | RANK #136 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Urothelial Carcinoma (43% recruiting · 86 trials)
Systemic Lupus Erythematosus lists 43 open slots (43% of 100 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Systemic Lupus Erythematosus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Systemic Lupus Erythematosus is recruiting above its size-band peers.
43 of 100 indexed trials (43%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Systemic Lupus Erythematosus trials is spread across many organizations.
Bristol-Myers Squibb accounts for 6 of 100 trials (6%). 64 distinct sponsors appear on at least one study for this condition label.
-
Typical Systemic Lupus Erythematosus enrolment sits around 135 participants.
Median target enrolment is 135 among the 100 trials that report a genuine target (sentinel values excluded). 44 of those (44%) plan for fewer than 100 participants.
-
Systemic Lupus Erythematosus research is mostly interventional.
83 interventional and 17 observational studies make up this index (83% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
100 total, page 1 of 2
Rheumatology Patient Registry and Biorepository
Yale University
NCT04402086
Study of Systemic Lupus Erythematosus
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT00001372
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
AbbVie
NCT05843643
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
Duke University
NCT03276923
Duke Lupus Registry
Duke University
NCT00512694
CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry
CorEvitas
NCT06804057
Systemic Lupus Erythematosus in Gullah Health
Medical University of South Carolina
NCT00756769
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
Hospital for Special Surgery, New York
NCT00198068
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Novartis Pharmaceuticals
NCT06133972
Intervention to Improve Communication and Medication Adherence in Lupus
Duke University
NCT06458075
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
UCB Biopharma SRL
NCT06617325
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
AstraZeneca
NCT06659029
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
GlaxoSmithKline
NCT06411249
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
NYU Langone Health
NCT05799378
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
State University of New York - Upstate Medical University
NCT00775476
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT05869955
Safety of the Herpes Zoster Subunit Vaccine in Lupus
NYU Langone Health
NCT05559671
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Amgen
NCT06570798
Creating Health Course Study for People With Rheumatological Conditions
Terry L. Wahls
NCT07180537
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
Zenas BioPharma (USA)
NCT06559163
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
Genentech
NCT06984341
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
GlaxoSmithKline
NCT06576271
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
Sanofi
NCT05039840
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
AstraZeneca
NCT05835310
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
Children's National Research Institute
NCT04833465
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
AstraZeneca
NCT06916806
Safety and Efficacy of ONT01 in Lupus
Hospital for Special Surgery, New York
NCT07107659
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
AstraZeneca
NCT07201558
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
M.D. Anderson Cancer Center
NCT06434363
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT05440422
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
Northwell Health
NCT06378736
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
AbbVie
NCT06977724
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
Climb Bio
NCT07011043
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
IRIS Research and Development
NCT06581562
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Cabaletta Bio
NCT06121297
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
Ventus Therapeutics U.S.
NCT07260877
Alnuctamab for Refractory SLE (LATTE Study)
Icahn School of Medicine at Mount Sinai
NCT07219563
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
Stephan Grupp MD PhD
NCT05029336
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
Luminary Therapeutics
NCT06340750
Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
AstraZeneca
NCT06594068
REACT-01: Reversing Autoimmunity Through Cell Therapy
Seattle Children's Hospital
NCT06465147
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
LiveKidney.Bio
NCT06737380
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
Columbia University
NCT06518668
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb
NCT05617677
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
Bristol-Myers Squibb
NCT05620407
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
Novartis Pharmaceuticals
NCT05639114
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
NCT05540327
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
AstraZeneca
NCT04877691
Peer Approaches to Lupus Self-management
Medical University of South Carolina
NCT03734055
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
Hoffmann-La Roche
NCT04963296
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 30 |
| Phase 2 | 24 |
| Phase 3 | 15 |
| Phase 4 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Systemic Lupus Erythematosus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Systemic Lupus Erythematosus trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Systemic Lupus Erythematosus page
100 registered trials, 43 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 43 Systemic Lupus Erythematosus trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bristol-Myers Squibb sponsors the most Systemic Lupus Erythematosus trials on record, review their full trial history before evaluating a specific study. See Bristol-Myers Squibb's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Systemic Lupus Erythematosus condition card totals 100 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.